All In Biotech

Drug Trial Radar · NCT03485677

Safety and Efficacy of Eliglustat With or Without Imiglucerase in Pediatric Patients With Gaucher Disease (GD) Type 1 and Type 3

Open Label, Two Cohort (With and Without Imiglucerase), Multicenter Study to Evaluate Pharmacokinetics, Safety, and Efficacy of Eliglustat in Pediatric Patients With Gaucher Disease Type 1 and Type 3

Last checked: Nov 19, 2026Latest source record: Jun 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

57

Actual

Start

Apr 11, 2018

Primary completion

Dec 26, 2025

Study completion Dec 26, 2025

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Apr 2, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objective: Evaluated the safety and pharmacokinetics of eliglustat in pediatric participants (≥2 to \<18 years old). Secondary Objective: Evaluated the efficacy of eliglustat and quality of life in pediatric participants (≥2 to \<18 years old).

Conditions

  • Gaucher's Disease Type I
  • Gaucher's Disease Type III

Interventions

  • Eliglustat GZ385660Drug

    Pharmaceutical form: Capsule, Liquid Route of administration: Oral

  • Imiglucerase GZ437843Drug

    Pharmaceutical form: Powder for solution for infusion Route of administration: Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of pharmacokinetic (PK) parameter of eliglustat: CmaxTime frame: Weeks 2, 13, 26 and 52
  2. Assessment of PK parameter of eliglustat: AUCTime frame: Weeks 2 and 52
  3. Adverse EventsTime frame: Up to Week 364

Locations

21 sites in 10 countries. Site status is shown where the registry gives one.

  • Investigational Site Number : 0320001

    Buenos Aires, Argentina

  • Investigational Site Number : 1240002

    Calgary, Alberta, Canada

  • Investigational Site Number : 1240003

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240001

    Toronto, Ontario, Canada

  • Investigational Site Number : 2500002

    Bron, France

  • Investigational Site Number : 3800002

    Rome, Roma, Italy

  • Investigational Site Number : 3920001

    Tokyo, Japan

  • Investigational Site Number : 3920002

    Koshigaya, Saitama, Japan

  • Investigational Site Number : 6430001

    Moscow, Russia

  • Investigational Site Number : 6430004

    Moscow, Russia

  • Investigational Site Number : 6430005

    Saint Petersburg, Russia

  • Investigational Site Number : 6430002

    Tomsk, Russia

  • Investigational Site Number : 7240003

    Zaragoza, Spain

  • Investigational Site Number : 7240001

    Esplugues de Llobregat, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240002

    Barakaldo, Basque Country, Spain

  • Investigational Site Number : 7520002

    Gothenburg, Sweden

  • Investigational Site Number : 7520001

    Luleå, Sweden

  • Investigational Site Number : 7920004

    Adana, Turkey (Türkiye)

  • Investigational Site Number : 7920003

    Istanbul, Turkey (Türkiye)

  • Investigational Site Number : 7920002

    Izmir, Turkey (Türkiye)

  • Investigational Site Number : 8260002

    Birmingham, England, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.